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Salicylic acid (SA), which is central to defense mechanisms in plants and the principal metabolite of
aspirin, occurs naturally in man with higher levels of SA and its urinary metabolite salicyluric acid
(SU) in vegetarians overlapping with levels in patients on low-dose aspirin regimens. SA is widely
distributed in animal blood. Fasting for major colorectal surgery did not cause disappearance of SA
from plasma, even in patients following total proctocolectomy. A
13C6 benzoic acid load ingested by
six volunteers led, between 8 and 16 h, to a median 33.9% labeling of urinary salicyluric acid. The
overall contribution of benzoic acid (and its salts) to the turnover of circulating SA thus requires further
assessment. However, that SA appears to be, at least partially, an endogenous compound should
lead to reassessment of its role in human (and animal) pathophysiology.
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INTRODUCTION
In plants, salicylic acid (SA) is a ubiquitous secondary
metabolite pivotally concerned in initiation of the response to
a variety of physical, chemical, and biological insults (1). The
potent analgesic and antipyretic properties of plant extracts,
notably dried myrtle leaves and willow bark, had been known
for many centuries before the isolation of salicylic acid, as the
likely active principle, by Meyer in 1870 (2). Since synthesis
of aspirin (acetylsalicylic acid) by Hoffman in 1897, investiga-
tion has focused on the properties of that compoundsdesigned
as a pro-drug. Aspirin is very rapidly hydrolyzed, having a
plasma t1/2 of 20 min, to the deacetylated metabolite SA (2-
hydroxybenzoic acid), which has a half-life of between 2 and
4h( 3). However, the demonstration that aspirin acts by serine
side-chain acetylation of Cox-1 and Cox-2 isoforms, restricting
substrate access to the active sites of these enzymes, has
deﬂected attention from salicylic acid itself, although in vivo
SA is, despite weak, reversible Cox-1 and absent Cox-2
inhibition, as effective as aspirin in suppressing inﬂammation
(4). The inhibition of transcription of the Cox-2 gene by
micromolar concentrations of SA (5, 6) is the likely explanation.
Previous work by our group has demonstrated and conﬁrmed
the presence of SA in serum (7) and urine (8), where its
metabolite salicyluric acid (SU) predominates, from individuals
who had not recently consumed aspirin. The measured levels
were signiﬁcantly higher in vegetarians (9, 10), overlapping with
levels in patients on low-dose aspirin regimens, and our past
publications have focused on a dietary origin (11) of this
naturally occurring SA in man. However, conﬁrmation of the
contribution from fruit and vegetable consumption in the diet
to circulating SA levels in man (12) has demonstrated that
<20% of the variability in serum SA, measured by a sensitive
speciﬁc method, may derive from that source. Some circulating
SA in aspirin-naı ¨ve or -free individuals could possibly derive
from another dietary source or be of nondietetic origin.
In plants, SA is synthesized through the shikimic acid
pathway via isochorismate (13) or, probably predominantly, by
the phenyl-propanoid route via cinnamic and benzoic acids (14).
Benzoic acid is a natural constituent of plants, with high amounts
being found in fruits and berries (15, 16). That hippuric acid,
the main metabolite of benzoic acid, may be formed endog-
enouslyinmanwasdemonstratedbyformuladietfeeding(17,18).
In the Sprague-Dawley rat a radiolabel experiment showed
phenylalanine to be the likely precursor (17). Use of the
generally regarded as safe (GRAS) sodium benzoate as a food
preservative also contributes to human intake. With regard to
levels of regular intake, the FDA estimate is of 0.9-34 mg/
day as benzoic acid and 34-328 mg/day as sodium benzoate,
although much higher levels of sodium benzoatesup to 5 g
twice dailyshave been used therapeutically in the treatment of
acute hepatic encephalopathy. Thus, in this paper we have
determined whether the addition of benzoic acid to a standard-
ized diet produced any change in serum or urinary salicylates.
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Blood samples, serum or plasma, were obtained from animals at
the London Zoo or at the Department of Biological Services, University
of Glasgow. Blood was collected according to the approved codes of
practice of these institutions.
Six mice were treated with neomycin, 100 mg/kg/day, for 4 days
prior to collection of blood to reduce as much as possible the bacterial
content of their gastrointestinal tracts. Samples from germ-free
Sprague-Dawley rats were obtained from Charles River Ltd., Margate,
Kent, U.K.
All human studies were approved by the Dumfries and Galloway
Health Board Ethics Committee. Serum salicylic acid (SA) and urinary
SA and salicyluric acid (SU) levels were assayed according to the HPLC
methods described previously (7, 8).
The absence of any SA from the milk diet used in the preliminary
controlled diet study was conﬁrmed by total SA assay as we have
previously described (11).
A pilot study, to assess whether ingestion of benzoic acid might
raise endogenous SA levels, utilized weighed preprepared meals
(requiring only reheating) replicating exactly the same menu and ﬂuid
intake over each 4 days. Throughout, urine samples were collected every
12 h. Fasting blood samples were obtained daily and on the morning
of day 5. Two individuals were studied over 4 days of diet standardiza-
tion after being aspirin-free for 2 weeks; the benzoic acid doses used
were 1 g/day on days 3 and 4 in one subject and 2 g/day on these days
in the other.
Subsequently, a labeled study was undertaken over 3 days in six
individuals (four males, two females, ages 30-62 years) using a
standard protocol. On day 2 all six individuals received1go funiformly
ring-labeled
13C benzoic acid with each of their three main meals. Very
minor gastric upset was the only side effect in an individual who
preferred to take the benzoic acid unencapsulated.
For that experiment uniformly ring-labeled
13C benzoic acid (ring-
13C 99% pure) was supplied by Cambridge Isotope Laboratories Inc.
USA. Food and ﬂuid intake over the 3 days of the study were
standardized. Each individual completed a detailed diary of all oral
intake on day 1 and replicated that diet as closely as possible over the
next two days. Cumulative urine samples were collected every 8 h over
the whole 72 h of the study. The blood sampling protocol followed as
closely as possible was day 1, 5 × 2 h, and days 2 and 3, 8 × 2h ,t h e
ﬁrst sample on each day being taken fasting. The serum SA levels were
analyzed as areas under the SA level time curves over 0-6 h only as
missing values precluded 0-8 h analysis. Statistical analysis of the
total urinary SA and SU results was by nonparametric Friedman two-
way analysis of variance, using SPSS version 12.
Gas chromatography-mass spectrometry (GC-MS) of the day 2,
8-16 h, urine samples was then performed. Preliminary fractionation
was as described previously (8); samples prepared without internal
standard were chromatographed under the usual conditions (with the
electrochemical detector inactive), and the fraction between 1 min prior
to the retention time (tR) of SU and 1 min after the tR of SA was
collected.
Trimethylsilyl derivatives were prepared by treating the dried extracts
with a mixture of acetonitrile and N,O-bis(trimethylsilyl)triﬂuoroac-
etamide (50:50, v/v, 30 min, 60 °C).
GC-MS analysis was carried out on an Agilent 6890/5973 MSD
system (30 m × 0.25 mm i.d. DB5MS column) using both scanning
and selected ion monitoring methods. The main ion fragments of interest
were for SA m/z 267 (unlabeled) and m/z 273 (labeled) and for SU m/z
324 (unlabeled) and m/z 330 (labeled).
To obtain the mass spectra shown in part in Figure 1, aliquots of
all of the second-day 8-16 h urine samples were initially pooled prior
to derivatization. Data ﬁles were analyzed by the Automated Mass
Spectral Deconvolution and Identiﬁcation System (AMDIS; NIST,
Gaithersburg, MD; http://chemdata.nist.gov/mass-spc/amdis/).
Further aliquots from individual samples were then fractionated,
derivatized, and analyzed by selected ion monitoring to give the
individual results. The ratios quoted were calculated from the m/z ratios
of 273/267 for
13C6 SA and 330/324 for
13C6 SU.
RESULTS
As Table 1 shows, those species regarded as primarily
carnivorous had blood SA levels comparable to those measured
in herbivores. The highest levels we detected were in the range
associated with aspirin use in man, as comparison with our
appended published results (9, 11) shows, and only the
crustacean samples examined did not contain SA.
To examine the possibility of a gastrointestinal bacterial
source for SA, two small groups of germ-free mice were assayed
for SA. The pooled serum from six mice treated with neomycin,
100 mg/kg/day, for 4 days before sacriﬁce had a slightly higher
concentration of SA in serum (0.309 µmol/L) than the pooled
serum sample from six untreated animals (0.268 µmol/L).
Another germ-free animal model studied was the Sprague-
Dawley rat delivered by caesarean section, reared in a sterile
environment, and fed sterilized food. A group of eight such
germ-free animals had a pooled serum SA level of 0.166 µmol/
L, approximately 2.5 times greater than the pooled serum
salicylic acid level of 0.069 µmol/L from a group of control
animals. The net effect of minimizing or eliminating a contribu-
tion from colonic bacteria in these animal models was therefore
enhancement of serum SA levels in the host animal.
Throughout the preliminary controlled diet study, in a subject
who had taken no aspirin during the previous 2 weeks, there
was persistence of measurable serum SA throughout 3 days on
a milk/water diet (which was conﬁrmed by analysis to be free
Figure 1. Salicyluric acid in pooled urine sample: (a) partial mass spectrum obtained by gas chromatogrphaphy-mass spectrometry of a trimethylsilylated
extract of pooled urine (isotopically labeled peaks are indicated by asterisks at m/z values 199, 212, and 330); (b) partial library mass spectrum of the
di-trimethylsilyl derivative of standard salicyluric acid (o-hydroxyhippuric acid). Data were analyzed using the Automated Mass Spectral Deconvolution
and Identiﬁcation System (AMDIS; NIST, Gaithersburg, MD; http://chemdata.nist.gov/mass-sps/amdis).
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continued at a rate of around 2.1 µmol/24 h throughout the
period of dietary restriction. Blood samples were assayed for
SA at 12 h intervals, and the serum SA levels did not change
signiﬁcantly, not falling below 0.1 µmol/L (20 times the limit
of detection of the assay) over the 72 h of the study. These
data suggested that another source of SA was responsible for
the persistence of serum SA and the steady rate of excretion of
SA + SU throughout the time course of this experiment.
In six patients (Table 2) who had total colectomy or rectal
excision following standard preoperative bowel preparation low-
level serum SA (range ) 0.012-0.0847 µmol/L) was detected
and urinary SA + SU excretion persisted (median of individual
lowest levels ) 0.613 µmol/24 h, range ) 0.184-7.607) in all
subjects, for up to 5 days postoperatively, rising only on
refeeding.
During the pilot benzoic acid study in two subjects there was
little variation in serum SA levels, which were in the ranges of
0.44-0.53 and 0.023-0.047, respectively, with no downward
trend over the course of the experiment. The rate of combined
SA and SU excretion in urine, however, increased from median
levels of 3.87 (range ) 3.47-4.32) and 4.50 (range )
4.39-4.62) µmol/24 h over the ﬁrst 3 days of the study to 5.10
and 7.04 µmol/24 h, respectively, on day 4. That increase was
greater in the subject who had consumed2go fbenzoic acid
per day on days 3 and 4.
Further examination of the possible biosynthesis of SA in
man required a labeled precursor study. That showed variability
in total serum SA during the study, but in every individual the
highest serum SA measured during the 3 days occurred during
day 2sat a median time of 4 h (range ) 2-8 h) after the ﬁrst
dose of benzoic acid. The areas under the SA level time curves
conﬁrmed the highest serum levels were reached on day 2, but
that was not signiﬁcant. The highest level (Figure 2, p ) 0.052)
of combined SA + SU urinary excretion was observed in the
8-16 h sample after the initial dose of benzoic acid.
To ascertain whether any of the
13C6 label in the benzoic
acid administered could be detected in salicylates, we therefore
focused on the day 2, 8-16 h urine.
No
13C6 was detected in the samples obtained prior to
ingestion of labeled benzoic acid. In Figure 1 the marked peaks
(/) indicate fragments from the presence of the (six ringed)
13C-
labeled SU derivative (m/z 330), 6 mass units higher than the
unlabeled SU derivative (m/z 324). The
13C isotope was also
conﬁrmed in all six individual urine, day 2, 8-16 h samples
and accounted, by selective ion monitoring, for 0.4-10.9%
(median ) 3.4%) in the SA derivative and 6.8-43.1% (median
) 33.9%) in the SU derivative (Table 3). In addition, consider-
Table 1. Concentration of Salicylic Acid (SA) in the Blood of a Variety of Animals
Results in Animals
animal
phylogenetic
class [SA] (µmol/L) animal
phylogenetic
class [SA] (µmol/L) animal
phylogenetic
class [SA] (µmol/L)
burrowing owl Aves 9.854 tiger Mammalian 0.661
a Chinese alligator Reptilia 0.156
ne-ne Aves 5.609 brown trout Pisces 0.538 domestic cat Mammalian 0.144
Indian rhinoceros Mammalian 4.700 giraffe Mammalian 0.507 pond heron Aves 0.136
pygmy hippopotamus Mammalian 2.384 donkey Mammalian 0.473 gorilla Mammalian 0.125
agouti Mammalian 2.116 sacred ibis Aves 0.353 red faced spider monkey Mammalian 0.080
Asian elephant Mammalian 1.635 goat Mammalian 0.310 mouse Mammalian 0.078
Burmese python Reptilia 1.362 giant anteater Mammalian 0.293 rat Mammalian 0.069
rabbit Mammalian 1.129 collared peccary Reptilia 0.237 domestic cat (fed only meat) Mammalian 0.058
piglet Mammalian 1.010 African lion Mammalian 0.226
a chimpanzee Mammalian 0.033
Arabian oryx Mammalian 0.777 cow Mammalian 0.216 European shore crab Crustacea <0.005
sheep Mammalian 0.715 Gelada baboon Mammalian 0.210 prawn Crustacea <0.005
Results in Man (9, 11)
median (µmol/L) range (µmol/L)
vegetarians, n ) 37 0.110 0.04-2.47
nonvegetarians, n ) 39 0.070 0.02-2.00
southern Indian villagers, n ) 21 0.763 0.05-0.64
75 mg aspirin takers, n ) 14 10.03 0.23-25.40
limit of detection of the method ) 0.005 µmol/L
a Mean concentration in ﬁve animals.
Table 2. Patient Proﬁle
no. of
obs patient gender
age (years) at
time of
diagnosis diagnosis procedure/operation
days prior
to eating
a
serum SA
(µmol/L) median
(range)
lowest urine
(SA + SU,
µmol/24 h, median)
15 1 male 39 ulcerative colitis
with toxic megacolon
total colectomy with ileostomy 2 0.0624 (0.054-0.082) 0.368
6 2 female 59 second colon cancer
with multiple polyps
panproctocolectomy 3 0.037 (0.013-0.074) 0.470
12 3 female 68 carcinoma of rectum abdomino-perineal resection 5 0.045 (0.012-0.132) 7.707
11 4 male 47 carcinoma of colon extended r. hemicolectomy 2 0.074 (0.061-0.088) 0.288
4 5 female 64 carcinoma of rectum low ant. resection of rectum 2 0.34 (0.079-0.847) 1.01
3 6 male 66 carcinoma of rectum +
second cancer in cecum
panproctocolectomy with ileostomy 2 0.103 (0.063-0.174) 1.84
a Patients were either fasting or receiving parenteral nutrition with no salicylic acid content (conﬁrmed by assay).
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13C6-labeled hippuric acid were
found (data not shown).
DISCUSSION
There is now no doubt that salicylic acid and its salts are
components of the human diet (11, 19-22). Although the
bioavailability of dietary salicylates was estimated to be low
(23), it is clear that serum SA levels in some aspirin-free
vegetarian subjects and populations (9, 11) overlap with those
of patients on low-dose aspirin regimens. One particularly
revealing recent observation, in a study which conﬁrmed that
circulating SA levels related to fruit and vegetable consumption,
was that <20% of the variability in serum SA derived from
that source (12).
Results of SA levels in a large variety of animals showed
that those species regarded as primarily carnivorous had levels
comparable to those measured in herbivores. Some bacteria,
notably mycobacterial, yersinia, and pseudomonas species,
synthesize SA to enhance iron chelation, so there was a
possibility that gut, particularly colonic, bacteria might be the
source of SA not readily explicable by lack of dietary exposure.
However, preliminary study of two germ-free animal models
reported here showed the net effect of minimizing or eliminating
a contribution from colonic bacteria was, in fact, an increase in
serum SA levels.
It was these animal observations which led us to postulate
that serum SA levels in aspirin-free individuals may be, at least
partially, endogenous. That salicylate levels in serum and urine
plateaued in a subject on a water/milk diet for 3 days should
be considered in light of a SA half-life of 4 h, which would
cause the serum SA level to fall to ∼0.004% of its initial level
at the end of this time interval. The levels of serum SA in the
fasting surgical patients study supported these milk diet observa-
tions. Persistence of low levels of serum SA and combined
urinary SA + SU excretion in the two patients who had
panproctocolectomy, and therefore no colonic or dietary source
of SA, was considered to be particularly strong evidence for an
endogenous source of this simple organic molecule.
The recourse to benzoic acid as a possible SA precursor in
man was directed by the relevant plant biochemistry (14) and
its prevalence in fruits and berries (15, 16). Benzoic acid may
also considered to be formed in vivo (17, 18) and is well-known
to be an acceptable diet additive.
Given the relatively high doses (1-2 g/day) used in the
preliminary benzoic acid study, the increase in SA levels
observed on the last day of that protocol might be thought to
be a little disappointing. The ﬁndings led us to use a slightly
higher benzoic acid dose for the labeled study. Even with that
higher benzoic acid dose, the increased total SA and SU urinary
excretion was not signiﬁcant, although clearly very marked in
some individuals. Whereas the renal excretion of SA depends
strongly on pH and the presence of organic acids as well as
urinary ﬂow rate (3), these possible confounding factors should
reduce SA plus SU excretion under the conditions of this small
study. Moreover, in a study of SA metabolism (to SU) using
the isolated perfused rat kidney, the addition of the competitive
substrate benzoic acid produced a rapid formation and excretion
of hippuric acid with corresponding inhibition of SU formation
and excretion (24). It would not, therefore, be surprising if use
of a larger dose of benzoic acid in a greater number of subjects
should lead to signiﬁcantly increased total salicylate excretion.
However, it is likely that naturally occurring benzoic acid was
contributing to the modest 20% variability in serum SA from
fruits and vegetables in the diet (12), although the added sodium
benzoate content of diets with considerable fruit and vegetable
content would probably be low. Given the widespread use of
sodium benzoate as an additive food preservative, further work
on its contribution to serum SA levels may be justiﬁed.
However, set against the nonsigniﬁcant increase of total SA and
SU levels in the day 2 8-16 h urines, the extent of SU
13C6
labeling we determined in these samples might be considered
to be surprising and may point to bioregulation of endogenous
serum SA.
For more than a century the focus has predominantly been
on the properties of aspirin, the pro-drug of SA. It is only
recently that the in vivo efﬁcacy of SA as an anti-inﬂammatory
has been adequately explainedsin terms of inhibition of Cox-2
gene transcription. Given the lability of its acetyl ester (aspirin)
within the narrow pH range of 2-3, other in vitro Cox-
independent effects, such as mediation of apoptosis (25) and
inhibition of angiogenesis (26), may also be attributable to SA
rather than its pro-drug. Other diverse effects of SA continue
to be reported, such as the surprising protective effects of lower
dose SA in a mouse heart model of myocardial ischemia (27).
The mechanism by which aspirin (and SA in vitro) has
antitumoral actions is unclear, but a recent observation that cell
proliferation is dependent on mitochondrial Ca
2+ uptake and
inhibited by low-level SA may be relevant (28).
SA is widely found in the animal kingdom. We have adduced
evidence for its biosynthesis from benzoic acid in man. These
observations are, we suggest, appropriately assessed in light of
the many effects of aspirin, its pro-drug. It is, we suspect,
Figure 2. Urinary SA + SU excreted throughout time course of
13C
experiment: total SA + SU excreted during the 8 h urine collection periods.
The columns represent the median value and the error bars the maximum
and minimum values. The dotted line at 24 h shows the point at which
the ﬁrst dose of benzoic acid was introduced. One subject was omitted
because of incomplete data.
Table 3. Isotopic Enrichment of Salicylic Acid (SA) and Salicyluric Acid
(SU) in Individual Urines
a
sample SA %
13C6 m/z 273/267 SU %
13C6 m/z 330/324
urine 1 0.06 31.29
urine 2 3.31 43.07
urine 3 0.41 6.82
urine 4 10.91 36.53
urine 5 3.50 23.96
urine 6 5.45 36.98
pooled urine (no
13C6) 0.00 0.00
standard soln SA 0.00 0.00
standard soln SU 0.00 0.00
a Urines 1-6 show the relevant m/z ratio values, for each individual, of
13C6-
labeled urinary salicylic acid (SA) and salicyluric acid (SU) SA, unlabeled 267,
labeled 273 SU, unlabeled 324, labeled 330. Also shown are results for pooled,
unlabeled (day 1) urine and for standard solutions of SA and SU.
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broadly defensive, role in animals as in plants. This simple
organic chemical is, we propose, likely to become increasingly
recognized as an animal bioregulator, perhaps in a class of its
own. Intriguingly, as a phytohormone it may have differential,
concentration-dependent, effects on programmed cell death and
surrounding tissue protection (29). Some of the tissue effects
of SA already described (5, 6, 25-28) raise the probability of
just such a hybrid function, perhaps at a critical point in
apoptosis and/or inﬂammation, in animals as in plants.
If we are right that SA is not just an important phytochemical
but also a key biopharmaceutical, its circulating level might well
be subject to homeostatic control and not be solely inﬂuenced
by dietary SA with or without benzoic acid intake.
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